Browse the evidence

Abdominal (visceral) obesity is the primary initiator of metabolic syndrome, driving insulin resistance and multi-organ metabolic derangements through elevated free fatty acids, reduced adiponectin, and leptin resistance.

Focus on reducing visceral fat through lifestyle changes rather than just total weight loss. Regular physical activity and dietary adherence (e.g., Mediterranean diet) are key interventions to offset insulin resistance and reduce the risk of metabolic syndrome, regardless of total BMI.

Insulin resistance is the essential common denominator of metabolic syndrome, driven by intracellular lipid accumulation (FFA, diacylglycerol) which interferes with insulin signaling pathways (IRS-1 phosphorylation).

Improving insulin sensitivity through exercise and diet can break the cycle of metabolic syndrome. Exercise stimulates skeletal muscle oxidative enzymes and mitochondrial biogenesis, directly counteracting the insulin resistance caused by intracellular lipid accumulation.

Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.

Unlike insulin, Tirzepatide does not increase the risk of low blood sugar (hypoglycemia) when used alone. In fact, it has a lower risk of causing hypoglycemia compared to basal insulin. This makes it a safer option for patients who are concerned about blood sugar lows.

SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular benefits (reduced MACE and heart failure hospitalization) and slow kidney disease progression, distinct from older glucose-lowering drugs.

If you have Type 2 Diabetes and heart or kidney issues, ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga) or GLP-1 agonists (like Ozempic, Trulicity). These drugs protect your heart and kidneys beyond just lowering sugar, unlike older diabetes medications.

Sleep restriction (4-5 hours per night) causes hormonal changes characterized by decreased leptin and increased ghrelin, leading to increased hunger, appetite, and a preference for high-carbohydrate and high-fat foods.

If you are sleep-deprived, your body is biologically wired to make you hungrier and crave carbs and fats. Recognize this as a hormonal response, not a personal failure. Prioritize sleep to regulate these hormones naturally.

Bariatric surgery resolves obesity-associated gonadal dysfunction (PCOS in women, MOSH in men) in the vast majority of severely obese patients, with resolution rates of 96% for PCOS and 87% for MOSH.

If you are severely obese and have been diagnosed with PCOS or Male Obesity-Associated Secondary Hypogonadism (MOSH), bariatric surgery is the most effective treatment for resolving these conditions. Unlike diet or medication which often only manage symptoms, surgery addresses the underlying metabolic drivers, leading to resolution in nearly all women with PCOS and most men with MOSH. Consult a bariatric specialist to see if you are a candidate.

Bariatric surgery reverses the sex-specific hormonal imbalances caused by obesity: it increases testosterone in men and decreases testosterone in women, while increasing SHBG and decreasing estradiol in both.

Bariatric surgery normalizes sex hormones in a sex-specific way. Men typically see their testosterone levels rise to normal ranges, while women see their elevated testosterone levels drop. Both groups see an increase in Sex Hormone Binding Globulin (SHBG) and a decrease in Estradiol. This hormonal normalization is key to resolving fertility and sexual health issues associated with obesity.

Obesity-associated gonadal dysfunction is highly prevalent in severely obese patients, affecting 36% of women (PCOS) and 64% of men (MOSH).

If you are severely obese, you are at high risk for hormonal reproductive issues. About 1 in 3 severely obese women has PCOS, and nearly 2 in 3 severely obese men has low testosterone (MOSH). Screening for these conditions is recommended during initial diagnostic workup for severe obesity.

Physiologic testosterone replacement (300 mcg/day transdermal patch) significantly increases bone mineral density at the hip and radius, fat-free mass, and thigh muscle cross-sectional area in women with hypopituitarism-induced androgen deficiency.

For women with hypopituitarism and low testosterone, a physiologic dose of transdermal testosterone (300 mcg/day) improves bone density at the hip and radius, increases muscle mass, and improves mood and sexual function without increasing body fat. This treatment is well-tolerated, though mild skin irritation is common. It does not significantly improve spine bone density.

Physiologic testosterone replacement improves mood and sexual function (libido, arousal, behavior/experience) in women with hypopituitarism.

For women with hypopituitarism and low testosterone, physiologic testosterone replacement improves mood, reduces depression, and enhances sexual function (libido, arousal, and sexual experience). These benefits occur without significant changes in cognitive function or body fat.

Plasma ghrelin levels increase with fasting and decrease after meals, with levels being higher after diet-induced weight loss compared to gastric bypass surgery.

When you lose weight through dieting, your body naturally increases ghrelin levels, making you hungrier. This is a biological response, not a personal failure. Gastric bypass surgery, by contrast, suppresses ghrelin levels, which may contribute to its effectiveness. Managing expectations about increased hunger during weight loss can help in adhering to long-term strategies.

Women with diabetes face a 58% greater risk of coronary heart disease (CHD) mortality and a 13% greater risk of all-cause mortality compared to men with diabetes, indicating a significant sex-specific disparity in cardiovascular outcomes.

If you are a woman with diabetes, your risk of dying from heart disease is significantly higher than a man with diabetes. This means you should not just manage your blood sugar, but actively prioritize cardiovascular health with your doctor, potentially requiring more aggressive monitoring or prevention strategies than standard male-centric guidelines might suggest.

Higher baseline insulin secretion is a key biological predictor of regression from pre-diabetes to normal glucose regulation, suggesting that preserving beta-cell function is critical for reversal.

Your body's ability to produce insulin is crucial for reversing pre-diabetes. The study found that people with higher insulin secretion were more likely to return to normal glucose levels. While you can't directly 'dose' insulin secretion, lifestyle interventions (diet and exercise) help preserve this function. This is particularly important for older adults, as age-related decline in insulin secretion can impede reversal. Focus on lifestyle changes to support your beta-cells.

Younger age is a significant predictor of regression from pre-diabetes to normal glucose regulation, likely due to better preserved insulin secretion and sensitivity.

Younger age is associated with a higher likelihood of reversing pre-diabetes, largely because younger people tend to have better insulin secretion and sensitivity. However, this does not mean older adults cannot benefit. Lifestyle interventions (diet and exercise) are still effective for older adults, though they may need to work harder to overcome age-related biological declines. The best strategy is to establish healthy habits early.

Metformin administration (1,700 mg/day) blunts gains in lean body mass and thigh muscle mass in older adults undergoing progressive resistance training.

If you are over 65 and taking metformin, expect less muscle gain from resistance training compared to someone not taking it. This is likely due to how metformin affects cellular signaling (mTOR/AMPK). Do not stop your medication without medical advice, but adjust your expectations for muscle growth.

Once-weekly subcutaneous semaglutide 2.4 mg reduces the risk of major kidney composite endpoints (including macroalbuminuria and persistent eGFR decline) in patients with overweight/obesity and established cardiovascular disease, regardless of diabetes status.

If you have obesity and heart disease but no diabetes, semaglutide 2.4mg weekly offers significant kidney protection. It reduces the risk of serious kidney events like needing dialysis or developing heavy protein in the urine. While there is a temporary initial dip in kidney filtration numbers, long-term outcomes are better than placebo. This is a standard-of-care option for kidney risk reduction in this specific high-risk group.

Semaglutide 2.4 mg slows the rate of eGFR decline and reduces albuminuria (UACR) in patients with overweight/obesity, with greater benefits observed in those with baseline eGFR <60 ml/min/1.73m².

For patients with existing kidney impairment (eGFR <60), semaglutide not only slows further decline but may actually improve eGFR readings compared to placebo. It also significantly reduces albuminuria (protein in urine), a key marker of kidney stress. This benefit is consistent across subgroups.

Obesity is associated with decreased plasma adiponectin levels, which correlates with insulin resistance and an increased risk of type 2 diabetes.

Research shows that people with obesity often have lower levels of adiponectin, a hormone that helps regulate insulin sensitivity. This hormonal imbalance contributes to insulin resistance and increases the risk of type 2 diabetes. Understanding this biological link can help reduce self-blame and highlight the importance of addressing metabolic health through lifestyle changes and medical support.

Consumption of fructose or high-fructose corn syrup (HFCS) increases risk factors for metabolic syndrome and cardiovascular disease through rapid hepatic metabolism catalyzed by fructokinase C, which drives de novo lipogenesis and increases uric acid levels, independent of body weight gain.

Limit added sugars, specifically those containing fructose or high-fructose corn syrup (like soda and sweetened juices), regardless of whether you are trying to lose weight. The harm comes from how your liver processes fructose, which increases liver fat and bad cholesterol even if your weight stays the same. Focus on reducing sugar-sweetened beverages and replacing them with water or unsweetened options to lower metabolic risk.

Bariatric surgery (RYGB/VSG) provides superior sustained weight loss (13-27%) and T2D remission compared to pharmacological interventions, largely driven by endocrine changes rather than just mechanical restriction.

Bariatric surgery (like gastric bypass) is currently the most effective treatment for obesity, achieving 13-27% sustained weight loss and often curing type 2 diabetes. Its success is driven by hormonal changes (increased GLP-1/PYY) rather than just stomach size reduction. However, due to its invasive nature, it is reserved for extreme cases, driving the need for drugs that can mimic these hormonal effects.

Resistance exercise stimulates muscle hypertrophy primarily through the activation of the mTOR pathway via PKB, while endurance exercise stimulates mitochondrial biogenesis primarily through AMPK activation of PGC-1alpha.

Understanding that strength and endurance use different molecular switches helps explain why you cannot maximize both simultaneously. To build muscle, focus on high-intensity resistance to activate PKB/mTOR. To improve endurance, focus on duration to activate AMPK/PGC-1alpha.

Visceral obesity is strongly associated with the 'metabolic syndrome' (hypertension, hyperlipidemia, hyperinsulinemia, and insulin resistance), whereas subcutaneous fat is not.

Where you store fat matters more for your health than how much you weigh. If you have excess fat around your waist (visceral fat), you are at significantly higher risk for heart disease and diabetes compared to someone who stores fat in their hips or thighs (subcutaneous fat), even if their total weight is the same.

Low-protein diets (10-15% energy) result in a greater reduction in hsCRP compared to high-protein diets (25-30% energy) during weight maintenance, independent of glycemic index.

To further lower inflammation after weight loss, consider not over-consumption protein. A moderate protein intake (around 10-15% of calories) may support lower inflammatory markers (hsCRP) better than a high-protein diet, although lipid and blood pressure benefits were similar across protein levels.

Statins reduce cardiovascular events and inflammatory markers (CRP) but may increase the risk of new-onset diabetes, indicating a trade-off between cardiovascular protection and glycemic control.

Statins are highly effective at preventing heart attacks and strokes, even in people with normal cholesterol but high inflammation. However, they can slightly increase the risk of developing diabetes. For most people with cardiovascular risk, the heart protection outweighs this risk. Monitor your blood sugar if you start statins.